ReNeuron Group plc (RNUGF)

[georgejjl]

ReNeuron Group Plc (LON:RENE) insider John Edward Berriman acquired 80,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were bought at an average price of GBX 225 ($2.94) per share, for a total transaction of £180,000 ($235,201.88).

https://www.modernreaders.com/news/2019/04/19/reneuron-group-plc-rene-insider-buys-180000-in-stock.html

John Edward Berriman BEng, MBA, is Non-Executive Chairman of the Board of ReNeuron Group PLC. He was appointed to the Board in July 2011 and became Chairman in March 2015. He is the Chairman of Autifony Therapeutics Ltd and past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (sold to Bayer AG in 2014 and previously listed on the Oslo stock exchange). He is also a nonexecutive Director of Cytos AG (listed on the SIX Swiss exchange). Until its sale to Amgen in the spring of 2012 he was a Director of Micromet Inc. (listed on NASDAQ). Previously he was a Director of Abingworth Management, an international healthcare venture capital firm.

WHAT IS THE SALARY OF JOHN BERRIMAN?
As the Non-Executive Chairman of the Board of ReNeuron plc, the total compensation of John Berriman at ReNeuron plc is $31,000.

https://wallmine.com/otc/rnugf/officer/1141952/john-berriman

A total transaction of £180,000 ($235,201.88) is definitely a significant purchase at the market price.

Good luck and GOD bless,